Diabetes mellitus and cardiac arrhythmias
https://doi.org/10.51793/OS.2024.27.3.001
Abstract
Background. The relationship between diabetes mellitus, the development of arrhythmias and cardiac conduction disorders has not been sufficiently studied. Rhythm and conduction disorders are observed in diabetes mellitus in the form of atrial fibrillation and fluttering, ventricular tachycardia, ventricular fibrillation, sinoauricular, intraventricular and atrioventricular blockade, prolongation of the QT interval.
Objective. To analyze published works on the prevalence of atrial and ventricular arrhythmias, as well as conduction disorders in patients with diabetes mellitus.
Results. The analysis of studies on cardiac arrhythmias in patients with impaired carbohydrate metabolism was carried out. There is a high prevalence of atrial fibrillation in type 1 and type 2 diabetes mellitus. Diabetes mellitus is one of the most important risk factors for the development of atrial fibrillation and a predictor of its complications – stroke and thromboembolism. Diabetes mellitus increases the frequency of atrial fibrillation and other arrhythmias, and in combination with other risk factors, the frequency of life-threatening complications and the number of hospitalizations increases. Poorly compensated diabetes and concomitant diseases were associated with a higher incidence of arrhythmias. Diabetes mellitus is an independent predictor of atrioventricular block, including grade III. Prolongation of the QT interval also increases cardiovascular mortality in diabetes. The ambiguous role of hypoglycemic conditions in the development of arrhythmias is shown. Meta-analyses of the presented studies of sodium glucose cotransporter type 2 inhibitors demonstrate a decrease in the frequency of arrhythmias, especially atrial fibrillation and flutter. In cases of cardiac arrhythmias and diabetes mellitus, SGLT2i are represented by drugs with sufficiently high antiarrhythmic efficacy and having the greatest evidence base of arrhythmogenic action. The potential role of hypoglycemic drugs of various classes for the prevention of arrhythmias in patients with diabetes mellitus has been shown.
Conclusion. The link between diabetes mellitus and cardiac arrhythmias is obvious, although insufficient attention is paid to this aspect. The most common arrhythmia in diabetes is atrial fibrillation, although there are any other rhythm and conduction disorders. If there are arrhythmias or to prevent the risk of their development, it is necessary to take into account the prescribed hypoglycemic therapy.
About the Author
L. Yu. Morgunov
Federal State Autonomous Educational Institution of Higher Education Peoples' Friendship University of Russia, Medical Institute
Россия
Россия
Leonid Yu. Morgunov, Dr. of Sci. (Med.), Professor of the Department of Hospital Therapy with a Course of Endocrinology, Hematology and Clinical Laboratory Diagnostics
6 Miklukho-Maklaya str., Moscow, 117198
References
1. Spartalis M., Pantelidis P., Kontogiannis C., Paschou S. A., Spartalis E., Iliopoulos D. C., Siasos G. The Complex Relationship Between Diabetes and Cardiac Arrhythmias: Pathophysiology and Mechanisms. Curr Pharm Des. 2022; 28 (26): 2129-2130. DOI: 10.2174/1381612828666220720095433.
2. Abuelgasim E., Shah S., Abuelgasim B., Soni N., Thomas A., Elgasim M., Harky A. Clinical overview of diabetes mellitus as a risk factor for cardiovascular death. Rev Cardiovasc Med. 2021; 22 (2): 301-314. DOI: 10.31083/j.rcm2202038.
3. Svane J., Pedersen-Bernard Ul., Tfelt-Hansen J. Diabetes and the Risk of Sudden Cardiac Death. Curr Cardiol Rep. 2020; 22 (10): 112. DOI: 10.1007/s11886-020-01366-2.
4. Rawshani A., McGuire D. K., Omerovic E., Sattar N., McMurray J. J. V., Smith U., Redfors B., Bergfeldt L., Eliasson B., Borén J., Bhatt D. L., Bergstrom G., Rawshani A. Cardiac arrhythmias and conduction abnormalities in patients with type 2 diabetes. Sci Rep. 2023; 13 (1): 1192. DOI: 10.1038/s41598-023-27941-5.
5. Agarwal G., Singh S. K. Indian J Endocrinol Metab. Arrhythmias in Type 2 Diabetes Mellitus. 2017; 21 (5): 715-718. DOI: 10.4103/ijem.IJEM_448_16.
6. Movahed M.-R. Diabetes as a risk factor for cardiac conduction defects: a review. Diabetes Obes Metab. 2007; 9 (3): 276-281. DOI: 10.1111/j.1463-1326.2006.00609.x.
7. Upenkumar Patel, Rupak Desai, Rezwan Munshi, Palakkumar Patel, Makaryus A. N. Burden of arrhythmias and associated in-hospital mortality in acute decompensated diabetes mellitus. Proc (Bayl Univ Med Cent). 2021; 34 (5): 545-549. DOI: 10.1080/08998280.2021.1925810.
8. Proietti R., Russo V., Wu M. A., Maggioni A. P., Marfella R. Diabetes mellitus and atrial fibrillation: evidence of a pathophysiological, clinical and epidemiological association beyond the thromboembolic risk. G Ital Cardiol (Rome). 2017; 18 (3): 199-207. DOI: 10.1714/2674.27397.
9. Gumprecht J. J., Kalarus Z. Atrial fibrillation in patients with concomitant diabetes mellitus – what do we already know and what do we need to discover? Wiad Lek. 2022; 75 (1): 123-127. PMID: 35092260.
10. Yubi Lin, Hairui Li, Xianwu Lan, Xianghui Chen, Aidong Zhang, Zicheng Li. Mechanism of and therapeutic strategy for atrial fibrillation associated with diabetes mellitus. Scientific World Journal. 2013; 2013: 209428. DOI: 10.1155/2013/209428.
11. Papazoglou A. S., Kartas A., Moysidis D. V., Tsagkaris C., Papadakos S. P., Bekiaridou A., Samaras A., Karagiannidis E., Papadakis M., Giannakoulas G. Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation. Cardiovasc Diabetol. 2022; 21 (1): 39. DOI: 10.1186/s12933-022-01473-0.
12. Goudis C. A., Korantzopoulos P., Ntalas I. V., Kallergis E. M., Liu T., Ketikoglou D. G. Diabetes mellitus and atrial fibrillation: Pathophysiological mechanisms and potential upstream therapies. Int J Cardiol. 2015: 184: 617-622. DOI: 10.1016/j.ijcard.2015.03.052.
13. Baigalmaa Lkhagva, Ting-Wei Lee, Yung-Kuo Lin, Yao-Chang Chen, Cheng-Chih Chung, Satoshi Higa, Yi-Jen Chen Cells. Disturbed Cardiac Metabolism Triggers Atrial Arrhythmogenesis in Diabetes Mellitus: Energy Substrate Alternate as a Potential Therapeutic Intervention. 2022; 11 (18): 2915. DOI: 10.3390/cells11182915.
14. Tadic M., Cuspidi C. Type 2 diabetes mellitus and atrial fibrillation: From mechanisms to clinical practice. Arch Cardiovasc Dis. 2015; 108 (4): 269-276. DOI: 10.1016/j.acvd.2015.01.009.
15. Yildiz M., Lavie C. J, Morin D. P., Ahmet Afsin Oktay. The complex interplay between diabetes mellitus and atrial fibrillation. Expert Rev Cardiovasc Ther. 2022; 20 (9): 707-717. DOI: 10.1080/14779072.2022.2115357.
16. Juan Xu, Yimeng Sun, Dandan Gong, Yu Fan. Impact of preexisting diabetes mellitus on cardiovascular and all-cause mortality in patients with atrial fibrillation: a meta-analysis. Front Endocrinol (Lausanne). 2022; 13: 921159. DOI: 10.3389/fendo.2022.921159.
17. Aune D., Feng T., Schlesinger S., Janszky I., Norat T., Riboli E. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: A systematic review and meta-analysis of cohort studies: meta-analysis. J Diabetes Complications. 2018; 32 (5): 501-511. DOI: 10.1016/j.jdiacomp.2018.02.004
18. Siyu Guo, Yuwen Huang, Xiao Liu, Jianyong Ma, Wengen Zhu. Association of type 1 diabetes mellitus and risk of atrial fibrillation: Systematic review and meta-analysis. Diabetes Res Clin Pract. 2023; 199: 110629. DOI: 10.1016/j.diabres.2023.110629.
19. Alijla F., Buttia C., Reichlin T., Razvi S., Minder B., Wilhelm M., Muka T., Franco O. H., Bano A. Association of diabetes with atrial fibrillation types: a systematic review and meta-analysis. Cardiovasc Diabetol. 2021; 20 (1): 230. DOI: 10.1186/s12933-021-01423-2.
20. Papazoglou A. S., Kartas A., Samaras A., Vouloagkas I., Vrana E., Moysidis D. V., Akrivos E., Kotzampasis G., Baroutidou A., Papanastasiou A., Liampas E., Botis M., Karagiannidis E., Stalikas N., Karvounis H., Tzikas A., Giannakoulas G. Prognostic significance of diabetes mellitus in patients with atrial fibrillation. Cardiovasc Diabetol. 2021; 20 (1): 40. DOI: 10.1186/s12933-021-01232-7.
21. Pallisgaard J. L., Schjerning A.-M., Lindhardt T. B., Procida K., Hansen M. L., C. Torp-Pedersen, Gunnar H Gislason. Risk of atrial fibrillation in diabetes mellitus: A nationwide cohort study. Eur J Prev Cardiol. 2016; 23 (6): 621-627. DOI: 10.1177/2047487315599892.
22. Karayiannides S., Norhammar A., Landstedt-Hallin L., Friberg L., Lundman P. Prognostic impact of type 1 and type 2 diabetes mellitus in atrial fibrillation and the effect of severe hypoglycaemia: a nationwide cohort study. Eur J Prev Cardiol. 2022; 29 (13): 1759-1769. DOI: 10.1093/eurjpc/zwac093.
23. Bisson A., Bodin A., Fauchier G., Herbert J., Angoulvant D., Ducluzeau P. H., Lip G. Y. H., Fauchier L. Sex, age, type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a nationwide analysis. Observational Study Cardiovasc Diabetol. 2021; 20 (1): 24. DOI: 10.1186/s12933-021-01216-7.
24. Chisa Matsumoto, Hisao Ogawa, Yoshihiko Saito, Sadanori Okada, Hirofumi Soejima, Mio Sakuma, Izuru Masuda, Masafumi Nakayama, Naofumi Doi, Hideaki Jinnouchi, Masako Waki, Takeshi Morimoto. Incidence of atrial fibrillation in elderly patients with type 2 diabetes mellitus. BMJ Open Diabetes Res Care. 2022; 10 (2): e002745. DOI: 10.1136/bmjdrc-2021-002745.
25. Kumar N., Echouffo-Tcheugui J. B. Diabetes and atrial fibrillation in hospitalized patients in the United States. Clin Cardiol. 2021; 44 (3): 340-348. DOI: 10.1002/clc.23533.
26. Mantovani A., Csermely A., Taverna A., Cappelli D., Benfari G., Bonapace S., Byrne C. D., Targher G. Association between metabolic dysfunction-associated fatty liver disease and supraventricular and ventricular tachyarrhythmias in patients with type 2 diabetes. Diabetes Metab. 2023; 49 (2): 101416. DOI: 10.1016/j.diabet.2022.101416.
27. Haxha S., Halili A., Malmborg M., Pedersen-Bjergaard U., Philbert B. T., Lindhardt T. B., Hoejberg S., Schjerning A.-M., Ruwald M. H., Gislaso G. H., Torp-Pedersen C., Bang C. N. Type 2 diabetes mellitus and higher rate of complete atrioventricular block: a Danish Nationwide Registry. Eur Heart J. 2023; 44 (9): 752-761. DOI: 10.1093/eurheartj/ehac662.
28. Movahed M. R., Bahrami A., Manrique C., Hashemzadeh M.. Strong independent association between third-degree AV-block and diabetes mellitus using a large database. Diabetes Res Clin Pract. 2023; 205: 110948. DOI: 10.1016/j.diabres.2023.110948.
29. Kobayashi S., Nagao M., Asai A., Fukuda I., Oikawa S., Sugihara H. Severity and multiplicity of microvascular complications are associated with QT interval prolongation in patients with type 2 diabetes. J Diabetes Investig. 2018; 9 (4): 946-951. DOI: 10.1111/jdi.12772.
30. Aburisheh K., AlKheraiji M. F., Alwalan S. I., Isnani A. C., Rafiullah M., Mujammami M., Alfadda A. A. Prevalence of QT prolongation and its risk factors in patients with type 2 diabetes. BMC Endocr Disord. 2023; 23 (1): 50. DOI: 10.1186/s12902-022-01235-9.
31. Kaze A. D., Yuyun M. F., Erqou S., Fonarow G. C., Echouffo-Tcheugui J. B. Severe Hypoglycemia and Incidence of QT Interval Prolongation Among Adults with Type 2 Diabetes. J Clin Endocrinol Metab. 2022; 107 (7): e2743-e2750. DOI: 10.1210/clinem/dgac195.
32. Bernjak A., Novodvorsky P., Chow E., Iqbal A., Sellors L., Williams S., Fawdry R. A., Marques J. L. B., Jacques R. M., Campbel M. J., Sheridan P. J., Heller S. R. Cardiac arrhythmias and electrophysiologic responses during spontaneous hyperglycaemia in adults with type 1diabetes mellitus. Diabetes Metab. 2021; 47 (5): 101237. DOI: 10.1016/j.diabet.2021.101237.
33. Koektuerk B., Aksoy M., Horlitz M., Bozdag-Turan I., Turan R. G. Role of diabetes in heart rhythm disorders. World J Diabetes. 2016; 7 (3): 45-49. DOI: 10.4239/wjd.v7.i3.45.
34. Remme C. A. Sudden Cardiac Death in Diabetes and Obesity: Mechanisms and Therapeutic Strategies. Can J Cardiol. 2022; 38 (4): 418-426. DOI: 10.1016/j.cjca.2022.01.001.
35. Tudoran C., Tudoran M., Giurgi-Oncu C., Abu-Awwad A., Abu-Awwad S.-A., Voiţă-Mekereş F. Associations between Oral Glucose-Lowering Agents and Increased Risk for Life-Threatening Arrhythmias in Patients with Type 2 Diabetes Mellitus-A Literature Medicina (Kaunas). 2023; 59 (10): 1760. DOI: 10.3390/medicina59101760.
36. Attachaipanich T., Chattipakorn Si. C., Chattipakorn N. Potential roles of sodium-glucose co-transporter 2 inhibitors in attenuating cardiac arrhythmias in diabetes and heart failure. J Cell Physiol. 2022; 237 (5): 2404-2419. DOI: 10.1002/jcp.30727.
37. Kolesnik E., Scherr D., Rohrer U., Benedikt M., Manninger M., Sourij H., von Lewinski D. SGLT2 Inhibitors and Their Antiarrhythmic Properties. Int J Mol Sci. 2022; 23 (3): 1678. DOI: 10.3390/ijms23031678.
38. Hang-Long Li, Lip G. Y. H., Qi Feng, Yue Fei, Yi-Kei Tse, Mei-Zhen Wu, Qing-Wen Ren, Hung-Fat Tse, Cheung B.-M. Y., Kai-Hang Yiu. Sodiumglucose cotransporter 2 inhibitors (iSGLT2) and cardiac arrhythmias: a systematic review and meta-analysis. Cardiovasc Diabetol. 2021; 20 (1): 100. DOI: 10.1186/s12933-021-01293-8.
39. Hideyuki Kishima, Takanao Mine, Eiji Fukuhara, Ryo Kitagaki, Masanori Asakura, Masaharu Ishihara. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes After Catheter Ablation for Atrial Fibrillation. Randomized Controlled Trial. JACC Clin Electrophysiol. 2022; 8 (11): 1393-1404. DOI: 10.1016/j.jacep.2022.08.004.
40. Zelniker T. A., Bonaca M. P., Furtado R. H. M., Mosenzon O., Kuder J. F., Murphy S. A., Bhatt D. L., Leiter L. A., McGuire D. K, Wilding J. P. H., Budaj A., Kiss R. G., Padilla F., Gause-Nilsson I., Langkilde A. M., Raz I., Sabatine M. S., Wiviott S. D. Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights From the DECLARETIMI 58 TrialCirculation. 2020; 141 (15): 1227-1234. DOI: 10.1161/CIRCULATIONAHA.119.044183.
41. Fernandes G. C., Fernandes A., Cardoso R., Penalver J., Knijnik L., Mitrani R. D., Myerburg R. J., Goldberger J. J. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials. Heart Rhythm. 2021; 18 (7): 1098-1105. DOI: 10.1016/j.hrthm.2021.03.028.
42. Chao Li, Jie Yu, Hockham C., Perkovic V., Neuen B. L., Badve S. V., Houston L., Lee V. Y. J., Barraclough J. Y., Fletcher R. A., Mahaffey K. W., Heerspink H. J. L., Cannon C. P., N. Bruce, Arnott C. Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis. Diabetes Obes Metab. 2022; 24 (10): 1927-1938. DOI: 10.1111/dom.14772.
43. Ziwei Yin, Huizhen Zheng, Zhihua Guo. Effect of Sodium-Glucose Co-transporter Protein 2 Inhibitors on Arrhythmia in Heart Failure Patients with or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Front Cardiovasc Med. 2022; 9: 902923. DOI: 10.3389/fcvm.2022.902923.
44. Fawzy A. M., Rivera-Caravaca J. M., Underhill P., Fauchier L., Lip G. Y. H. Incident heart failure, arrhythmias and cardiovascular outcomes with sodiumglucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database.Diabetes Obes Metab. 2023; 25 (2): 602-610. DOI: 10.1111/dom.14854.
45. Ru-Jie Zheng, Yue Wang, Jun-Nan Tang, Jie-Ying Duan, Ming-Yue Yuan, Jin-Ying Zhang. Association of iSGLT2 With Risk of Atrial Fibrillation and Stroke in Patients with and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol. 2022; 79 (2): e145-e152. DOI: 10.1097/FJC.0000000000001183.
46. Scheen A. J. Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and АГПП1 receptor agonists. Diabetes Metab. 2022; 48 (6): 101390. DOI: 10.1016/j.diabet.2022.101390.
47. Wenjie Li, Xingqing Chen, Xiangqi Xie, Min Xu, Lingling Xu, Peiying Liu, Bihui Luo. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review with Network Meta-analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol. 2022; 79 (3): 281-288. DOI: 10.1097/FJC.0000000000001197.
48. Wence Shi, Wenchang Zhang, Da Zhang, Ge Ren, Pengfei Wang, Lihua Gao, Haonan Chen, Chunhua Ding. Comparison of the effect of glucoselowering agents on the risk of atrial fibrillation: A network metaanalysis. Heart Rhythm. 2021; 18 (7): 1090-1096. DOI: 10.1016/j.hrthm.2021.03.007.
49. Zhiwei Zhang, Xiaowei Zhang, Panagiotis Korantzopoulos, Konstantinos P Letsas, Gary Tse, Mengqi Gong, Lei Meng, Guangping Li, Tong Liu. Thiazolidinedione use and atrial fibrillation in diabetic patients: a metaanalysis. BMC Cardiovasc Disord. 2017; 17 (1): 96. DOI: 10.1186/s12872-017-0531-4.
50. Jiandong Zhou, Guoming Zhang, Carlin Chang, Oscar Hou In Chou, Sharen Lee, Keith Sai Kit Leung, Wing Tak Wong, Tong Liu, Abraham Ka Chung Wai, Shuk Han Cheng, Qingpeng Zhang, Gary Tse. Metformin versus sulphonylureas for new onset atrial fibrillation and stroke in type 2 diabetes mellitus: a population-based study. Acta Diabetol. 2022; 59 (5): 697-709. DOI: 10.1007/s00592-021-01841-4.
51. Ostropolets A., Elias P. A., Reyes Mi. V., Wan E. Y., Pajvani U. B., Hripcsak G., Morrow J. P. Metformin Is Associated with a Lower Risk of Atrial Fibrillation and Ventricular Arrhythmias Compared With Sulfonylureas: An Observational Study. Circ Arrhythm Electrophysiol. 2021; 14 (3): e009115. DOI: 10.1161/CIRCEP.120.009115.
52. Leonard C. E., Brensinger C. M., Aquilante C. L., Bilker W. B., Boudreau D. M., Deo R., Flory J. H., Gagne J. J., Mangaali M. J., Hennessy S. Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia. Diabetes Care. 2018; 41 (4): 713-722. DOI: 10.2337/dc17-0294.
53. Islam N., Ayele H. T., Yu O. H. Y., Douros A., Filion K. B. Sulfonylureas and the Risk of Ventricular Arrhythmias Among People with Type 2 Diabetes: A Systematic Review of Observational Studies. Clin Pharmacol Ther. 2022; 111 (6): 1248-1257. DOI: 10.1002/cpt.2570.
54. Leonard C. E., Sean Hennessy, Xu Han, Siscovick D. S., Flory J. H., Deo R. Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence. Trends Endocrinol Metab. 2017; 28 (8): 561-586. DOI: 10.1016/j.tem.2017.04.003.
Review
For citations:
Morgunov L.Yu. Diabetes mellitus and cardiac arrhythmias. Lechaschi Vrach. 2024;(3):7-15. (In Russ.) https://doi.org/10.51793/OS.2024.27.3.001
Views:
134
JATS XML
Email this article 
